@article{bbaaf772ddda4f919f62d1bc76544756,
title = "Docosahexaenoic acid supplementation of preterm infants and parent-reported symptoms of allergic disease at 7 years corrected age: Follow-up of a randomized controlled trial",
abstract = "Background: Docosahexaenoic acid (DHA, 22:6n-3) supplementation in the prenatal period is associated with a reduction in the incidence of some symptoms of allergic disease. Infants born preterm are at increased risk of allergic disease, but it is unknown if DHA supplementation reduces the risk of childhood allergies. Objectives: The aim of this study was to determine if supplementation of infants born at >33 wk gestation with high-DHA compared with standard-DHA enteral feeds decreases the incidence and severity of parent-reported allergic disease symptoms at a corrected age (CA) of 7 y. Methods: This study was a follow-up of an Australian multicenter randomized controlled trial. Infants were given high-DHA (-1% total fatty acids) or standard-DHA (-0.3% total fatty acids) enteral feeds from 2-4 d of postnatal age until 40 wk postmenstrual age. Parent-reported incidence of respiratory allergic disease symptoms including wheeze and rhinitis at 7 y CA were the main outcomes. Other outcomes included the incidence of eczema symptoms; severity of any symptoms; and the incidence of wheeze, rhinitis, rhinoconjunctivitis, and eczema from birth to 7 y CA. Results: Data were available for 569 of 657 (87%) children originally randomized. Symptoms of wheeze or rhinitis at 7 y CA did not differ between high-and standard-DHA groups [wheeze: RR: 1.10; 95% CI: 0.73, 1.65; P = 0.66; rhinitis: RR: 1.09; 95% CI: 0.81, 1.46; P = 0.59]. There was no difference in other allergic disease symptoms at 7 y CA or in the severity of symptoms. Parent-reported symptoms of wheeze, rhinitis, rhinoconjunctivitis, or eczema from birth to 7 y CA did not differ between the groups. Conclusions: High-dose DHA supplementation of infants born at >33 wk gestation did not alter allergic disease symptoms or severity at 7 y CA, or from birth to 7 y CA compared with standard-dose DHA.",
keywords = "?-3 Long-Chain Polyunsaturated Fatty Acids, Allergic Disease, Docosahexaenoic Acid, Prematurity, Preterm Infant",
author = "Gunaratne, {Anoja W.} and Maria Makrides and Carmel Collins and Robert Gibson and Andrew McPhee and Thomas Sullivan and Jacqueline Gould and Tim Green and Doyle, {Lex W.} and Davis, {Peter G.} and French, {Noel P.} and Colditz, {Paul B.} and Karen Simmer and Morris, {Scott A.} and Karen Best",
note = "Funding Information: The authors{\textquoteright} contributions were as follows—MM, KPB, CTC, RAG, PJA, AJM, TRS, PR, LWD, PGD, PBC, KS, and SAM: designed and conducted the original DINO trial; AWG, CTC, RAG, PJA, AJM, TRS, JEM, PR, JG, LWD, PGD, PBC, KS, SAM, and MM: designed and conducted the 7-y follow-up trial; AWG, CC, KB, TG, TRS, and MM: were involved in the analysis and interpretation of data and TRS carried out the statistical analyses; KPB: drafted the manuscript and all authors critically revised and edited the manuscript and approved the final submitted version; all other authors: had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis; and KPB: has primary responsibility for final content. All authors have completed the ICMJE uniform disclosure at www.icmje.org/coi_disclosure.pdf. AWG, AJM, TRS, TJG, LWD, NPF, PBC, KS, SAM, and KPB have nothing to disclose. Financial support for the submitted work was received from the National Health and Medical Research Council (NHMRC) Australia for the original trial (ID 250322) and 7-y follow-up study (ID 508003) and from Mead Johnson Nutrition for the 7-y follow-up study. Treatment and placebo capsules for the original trial were donated by Clover Corporation and infant formula was donated by Mead Johnson Nutrition and Nutricia Australasia. CTC reports grants from the NHMRC of Australia, nonfinancial support from Clover Corporation, Australia, and grants from Mead Johnson Nutrition, IN, during the conduct of the study. PGD reports grants from the Australian NHMRC, during the conduct of the study. Honoraria have been paid to JG{\textquoteright}s institution by the Nestle Nutrition Institute and Fonterra to support conference travel. MM reports grants from NHMRC Australia, and grants and nonfinancial support from Mead Johnson Nutrition, during the conduct of the study, and other support from Fonterra and from Nestle, outside the submitted work; RAG reports grants from NHMRC Australia, and grants and nonfinancial support from Mead Johnson Nutrition, during the conduct of the study, and other support from Fonterra, outside the submitted work. Funding Information: This work was supported by a 5-y project grant from the National Health and Medical Research Council (NHMRC), Australia (ID 508003) and Mead Johnson Nutrition. NHMRC Fellowships support MM (Principal Research Fellow APP1061704); RAG (Senior Principal Research Fellow APP1046207), PGD (Practitioner Fellow APP1059111), PBC (Practitioner Fellow APP511117). CTC was supported through a MS McLeod Postdoctoral Research Fellowship (MS McLeod Research Fund, Women{\textquoteright}s and Children{\textquoteright}s Hospital Research Foundation). The views expressed in this article are soley the responsibility of the authors and do not reflect the views of the NHMRC, Australia.",
year = "2019",
month = jun,
day = "1",
doi = "10.1093/ajcn/nqz010",
language = "English",
volume = "109",
pages = "1600--1610",
journal = "American Journal of Clinical Nutrition",
issn = "0002-9165",
publisher = "American Society for Nutrition",
number = "6",
}